Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nursing Ethical Principles II01:27

Nursing Ethical Principles II

2.4K
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
2.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

319
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

447
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
447
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same author

Comparing simulation modalities for health equity communication training in pharmacy education: A mixed-methods comparison of live-actor video, text-based, and AI-generated scenarios.

Currents in pharmacy teaching & learning·2026
Same author

Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy.

Pharmacogenomics·2026
Same author

Relationships Between Antihypertensive, Glucose- and Lipid-Lowering Medication Adherence, and Demographic and Clinical Characteristics in American Indian Adults With Type 2 Diabetes.

Journal of diabetes research·2026
Same author

Understanding the Factors Influencing Black Pharm.D. Student Engagement in Research: A Multi-Institutional Qualitative Study.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Response to the comment on "Long-lasting effect of penetrating acupuncture among responders: Double-blind RCT of acupuncture for vulvodynia".

The journal of pain·2026
Same journal

Bereaved Parents and Spouses as Educators in Pediatric Simulation: Ethical Reflections.

Journal of pain and symptom management·2026
Same journal

The Unplugged Patient: A Case Report on Bridging the Digital Divide in Palliative Care.

Journal of pain and symptom management·2026
Same journal

Barriers perceived by palliative care fellowships in training physicians from diverse specialties.

Journal of pain and symptom management·2026
Same journal

Health Equity: Foundation of Serious Illness Care.

Journal of pain and symptom management·2026
Same journal

Coping with Breathlessness in Individuals with Lung Diseases: A Systematic Review and Meta-Synthesis.

Journal of pain and symptom management·2026
Same journal

Growing the Next Generation of Hospice and Palliative Medicine Researchers.

Journal of pain and symptom management·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.5K

Racial Disparities in Non-Stigmatized Supportive Care Medication Use in Pancreatic Cancer.

Olga Monika Trejos Kweyete1, Chardaé Whitner2, David L Deremer3

  • 1Department of Pharmacotherapy and Translational Research (O.M.T.K.), University of Florida College of Pharmacy, Orlando, Florida, USA.

Journal of Pain and Symptom Management
|March 5, 2026
PubMed
Summary
This summary is machine-generated.

Racial disparities exist in supportive care medication use for pancreatic cancer patients. Black patients, for example, had lower use of antiemetics and sleep aids, highlighting ongoing inequities in end-of-life symptom management.

Keywords:
cachexiacancercancer survivorshiphealth disparitiesinsomniamediation use disparitiesmedicationnauseapancreatic cancersupportive care

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

655
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

4.1K

Related Experiment Videos

Last Updated: Mar 7, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.5K
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

655
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

4.1K

Area of Science:

  • Oncology
  • Health Services Research
  • Health Equity

Background:

  • Pancreatic cancer (PC) presents significant symptom burden, impacting quality of life.
  • Supportive care medications (SCMs) are crucial for managing PC symptoms.
  • Previous research identified racial disparities in SCMs, but less is known about non-stigmatized medications.

Purpose of the Study:

  • To investigate racial and ethnic disparities in the utilization of non-stigmatized SCMs.
  • To examine SCM use among patients with PC during the end-of-life (EOL) period.
  • To identify potential inequities in supportive care for diverse PC patient populations.

Main Methods:

  • Retrospective cohort study utilizing SEER-Medicare data (2005-2017).
  • Inclusion criteria: Patients with PC, continuous Medicare Parts A, B, D coverage, and death within 12 months of diagnosis.
  • SCM use defined by outpatient prescription claims for specific medication classes; multivariable logistic regression analyzed disparities.

Main Results:

  • The study included 74,309 PC patients across racial/ethnic groups.
  • Black patients showed lower use of antiemetics, headache aids, and sleep aids compared to White patients.
  • Black patients exhibited higher use of appetite stimulants and cognitive aids; similar patterns observed in other minority groups.

Conclusions:

  • Persistent racial and ethnic disparities in non-stigmatized SCM use among EOL PC patients were confirmed.
  • These findings underscore existing inequities in cancer symptom management.
  • Interventions are needed to ensure equitable access to SCMs for all diverse patient populations.